Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Tfeb Links MYC Signaling to Epigenetic Control of Acute Myeloid Leukemia Cell Death and Differentiation

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-137209

Published: 2020

Journal Articles

Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures

Blood (2019) 134 (Supplement_1): 1710.

https://doi.org/10.1182/blood-2019-123877

Published: 2019

Journal Articles

A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)

Guru Subramanian Guru Guru Murthy, MBBS, Scott H. Kaufmann, MD PhD, Aniko Szabo, PhD, Arielle Baim, Ashish Anshu, Alexander Hinman, Laura C. Michaelis, MD, Sameem Abedin, MD, Karen-Sue B. Carlson, MD PhD, Lyndsey Runaas, MD, Ehab L. Atallah, MD

Blood (2019) 134 (Supplement_1): 3837.

https://doi.org/10.1182/blood-2019-131728

Published: 2019

Journal Articles

Topoisomerase I-DNA Covalent Complexes in Myeloid Malignancies: A Potential Biomarker for Topoisomerase I Inhibitor Sensitivity

Mira A. Kohorst, MD, Karen S. Flatten, Kevin L. Peterson, Paula A. Schneider, Cristina Correia, Keith W. Pratz, MD, B. Douglas Smith, MD, Scott H. Kaufmann, MD PhD

Blood (2018) 132 (Supplement 1): 5146.

https://doi.org/10.1182/blood-2018-99-115667

Published: 2018

Journal Articles

Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia

Jonathan Allen Webster, MD, Raoul Tibes, MD PhD, Amanda Blackford, ScM, Lawrence Morris, MD, Mrinal M Patnaik, MBBS, Lihua Wang, PhD, Melanie Rebechi, BS, Jacqueline Greer, RN, Mark R Litzow, MD, Larry Karnitz, PhD, Gary L. Rosner, Austin Doyle, MD, Scott H. Kaufmann, MD PhD, Judith E Karp, MD, B. Douglas Smith, MD

Blood (2015) 126 (23): 2563.

https://doi.org/10.1182/blood.V126.23.2563.2563

Published: 2015

Journal Articles

MTH1 Inhibitor-Induced Cytotoxicity in Acute Myeloid Leukemia

Mithun Vinod Shah, MD PhD, Karen S. Flatten, B. Douglas Smith, MD, Allan D. Hess, PhD, Scott H. Kaufmann, MD PhD

Blood (2015) 126 (23): 1273.

https://doi.org/10.1182/blood.V126.23.1273.1273

Published: 2015

Journal Articles

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Leukemias

Blood (2015) 126 (23): 1361.

https://doi.org/10.1182/blood.V126.23.1361.1361

Published: 2015

Journal Articles

mTOR Dual Inhibitor Induced Cytotoxicity Depends on 4EBP1/c-Myc/Puma and NFkB/Egr-1/Bim Pathways in Human Lymphoid Malignancies

Seongseok Yun, MD PhD, Nicole D. Vincelette, Katherine L. B. Knorr, PhD, Luciana L. Almada, PhD, Paula A. Schneider, Kevin L. Peterson, PhD, Karen S. Flatten, Allan D. Hess, PhD, B. Douglas Smith, MD, Judith E. Karp, MD, Martin E. Fernandez-Zapico, MD, Scott H. Kaufmann, MD PhD

Blood (2015) 126 (23): 3705.

https://doi.org/10.1182/blood.V126.23.3705.3705

Published: 2015

Journal Articles

A Randomized Phase II Trial of Three Novel Regimens for Relapsed/ Refractory Acute Myeloid Leukemia (AML) Demonstrates Encouraging Results with a Flavopiridol-Based Regimen: Results of Eastern Cooperative Oncology Group (ECOG) Trial E1906

Mark R. Litzow, MD, Xin Victoria Wang, PhD, Martin P. Carroll, MD, Judith E. Karp, MD, Rhett Ketterling, MD, Scott H. Kaufmann, MD PhD, Hillard M. Lazarus, Selina M. Luger, MD, Elisabeth M. Paietta, PhD, Jacob M. Rowe, MD, Jessica K Altman, Keith W Pratz, MD, E. Randolph Broun, MD, Martin S. Tallman, MD

Blood (2014) 124 (21): 3742.

https://doi.org/10.1182/blood.V124.21.3742.3742

Published: 2014

Journal Articles

Investigation of MLN4924 Alone and in Combination with Bcl-2 Inhibitors in Hematopoietic Stem Cells and Progenitors in Acute Myelogenous Leukemia

Katherine L. B. Knorr, B. Douglas Smith, MD, Allan D. Hess, PhD, Judith E. Karp, MD, Scott H. Kaufmann, MD PhD

Blood (2014) 124 (21): 3603.

https://doi.org/10.1182/blood.V124.21.3603.3603

Published: 2014

Journal Articles

Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies

Meera Sridharan, MD, PhD, Aref Al-Kali, MD, Aneel A. Ashrani, MBBS, MSc, Kebede Begna, MD, Michelle Elliott, William J. Hogan, MBChB, Carl C. Hook, MD, Scott H. Kaufmann, MD, PhD, Louis Letendre, MD, Mark R. Litzow, MD, Mrinal M. Patnaik, MBBS, Animesh D. Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Alexandra Wolanskyj, MD, Rajiv K. Pruthi, MBBS

Blood (2013) 122 (21): 5000.

https://doi.org/10.1182/blood.V122.21.5000.5000

Published: 2013

Journal Articles

Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio

Jeffrey E Lancet, MD, Eric Feldman, MD, Matthew C Foster, MD, Ivana Gojo, MD, Olatoyosi Odenike, MD, Rami S. Komrokji, MD, Roger Strair, MD, PhD, Scott H. Kaufmann, MD, PhD, Roland Knoblauch, MD, PhD, J. D. Karkera, PhD, John J Wright, MD, PhD, Judith E. Karp, MD

Blood (2012) 120 (21): 1508.

https://doi.org/10.1182/blood.V120.21.1508.1508

Published: 2012

Journal Articles

Phase I Trial of the Oral Poly (ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888, V) Combined Wtih Topoecan (T) and Carboplatin (C) for Adults with Relapsed and Refractory Acute Leukemias,

Keith W. Pratz, MD, Scott H. Kaufmann, MD, PhD, Mark R. Litzow, MD, Jiuping Ji, PhD, Alice Chen, MD, Michelle A Rudek, Judith E. Karp, MD

Blood (2011) 118 (21): 3634.

https://doi.org/10.1182/blood.V118.21.3634.3634

Published: 2011

Journal Articles

Genetic and Epigenetic Defects in DNA Repair Lead to Synthetic Lethality of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors in Aggressive Myeloproliferative Disorders

Michael A McDevitt, MD, PhD, Brian D Koh, Anand Patel, Alison R. Moliterno, MD, Weijie Poh, James G. Herman, MD, Robert L Dilley, B. Douglas Smith, M.D., Judith E. Karp, MD, Jaroslaw P Maciejewski, MD, PhD, Scott H. Kaufmann, MD, PhD, Keith W. Pratz, MD

Blood (2011) 118 (21): 400.

https://doi.org/10.1182/blood.V118.21.400.400

Published: 2011

Journal Articles

Phase I Dose-Escalation Study of SCH 900776 in Combination with Cytarabine (Ara-C) in Patients with Acute Leukemia

Brian M. Thomas, MD, Scott H. Kaufmann, MD, PhD, Jacqueline M Greer, RN, Steven D. Gore, MD, Keith W. Pratz, MD, B. Douglas Smith, MD, Karen Mackey, RN, Sabine Loechner, MPA, Jo Ann Horowitz, MD, Judith E. Karp, MD

Blood (2011) 118 (21): 1531.

https://doi.org/10.1182/blood.V118.21.1531.1531

Published: 2011

Journal Articles

Phase I Trial of the Oral Poly (ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888, V) Combined Wtih Topoecan (T) and Carboplatin (C) for Adults with Relapsed and Refractory Acute Leukemias

Judith E. Karp, MD, Keith W Pratz, MD, Mark R. Litzow, MD, Jiuping Ji, PhD, Alice Chen, MD, Michelle Rudek, PharmD, PhD, Scott H. Kaufmann, MD, PhD

Blood (2010) 116 (21): 3276.

https://doi.org/10.1182/blood.V116.21.3276.3276

Published: 2010

Journal Articles

OSI-027, a Dual TORC1/TORC2 Inhibitor, Induces Bim- and Puma-Mediated Apoptosis In Lymphoid Malignancy

Andrea E. Wahner Hendrickson, MD, Mamta Gupta, Ph.D, Seongseok Yun, Jennifer C. Shing, Paula A. Schneider, Kevin L. Peterson, Judith E. Karp, MD, Sharon Barr, Thomas E. Witzig, MD, Scott H. Kaufmann, MD, PhD

Blood (2010) 116 (21): 970.

https://doi.org/10.1182/blood.V116.21.970.970

Published: 2010

Journal Articles

Dual Inhibition of mTORC1/mTORC2 Induces Apoptosis of Mantle Cell Lymphoma by Preventing Rictor Mediated AKT S473 Phosphorylation by Potentiating AKT2-PHLPP1 Association

Mamta Gupta, Ph.D, Andrea Wahner Hendrickson, Jing Jing Han, Mary Stenson, Linda Wellik, Sharon Barr, Scott H. Kaufmann, MD, PhD, Thomas E. Witzig, MD

Blood (2010) 116 (21): 772.

https://doi.org/10.1182/blood.V116.21.772.772

Published: 2010

Journal Articles

A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas

Blood (2010) 116 (21): 287.

https://doi.org/10.1182/blood.V116.21.287.287

Published: 2010

Journal Articles

Combinations of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, MS-275) and Imatinib Have Divergent Effects in Imatinib-Sensitive Vs. Imatinib-Resistant p210- BCR/ABL Expressing Cell Lines.

Rachel E. Rau, MD, Emily McIntyre, Scott H. Kaufmann, MD, PhD, Igor Espinoza-Delgado, MD, Judith Karp, Patrick Brown, MD

Blood (2009) 114 (22): 2742.

https://doi.org/10.1182/blood.V114.22.2742.2742

Published: 2009

NARROW

Tfeb Links MYC Signaling to Epigenetic Control of Acute Myeloid Leukemia Cell Death and Differentiation

Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures

A Multisite Phase Ib Study of Pevonedistat, Azacitidine and Venetoclax (PAVE) for the Treatment of Subjects with Acute Myelogenous Leukemia (AML)

Topoisomerase I-DNA Covalent Complexes in Myeloid Malignancies: A Potential Biomarker for Topoisomerase I Inhibitor Sensitivity

Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia

MTH1 Inhibitor-Induced Cytotoxicity in Acute Myeloid Leukemia

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Leukemias

mTOR Dual Inhibitor Induced Cytotoxicity Depends on 4EBP1/c-Myc/Puma and NFkB/Egr-1/Bim Pathways in Human Lymphoid Malignancies

A Randomized Phase II Trial of Three Novel Regimens for Relapsed/ Refractory Acute Myeloid Leukemia (AML) Demonstrates Encouraging Results with a Flavopiridol-Based Regimen: Results of Eastern Cooperative Oncology Group (ECOG) Trial E1906

Investigation of MLN4924 Alone and in Combination with Bcl-2 Inhibitors in Hematopoietic Stem Cells and Progenitors in Acute Myelogenous Leukemia

Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies

Phase 2 Trial of the Farnesyltransferase Inhibitor Tipifarnib in Previously Untreated Older Adults with AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio

Phase I Trial of the Oral Poly (ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888, V) Combined Wtih Topoecan (T) and Carboplatin (C) for Adults with Relapsed and Refractory Acute Leukemias,

Genetic and Epigenetic Defects in DNA Repair Lead to Synthetic Lethality of Poly (ADP-Ribose) Polymerase (PARP) Inhibitors in Aggressive Myeloproliferative Disorders

Phase I Dose-Escalation Study of SCH 900776 in Combination with Cytarabine (Ara-C) in Patients with Acute Leukemia

Phase I Trial of the Oral Poly (ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888, V) Combined Wtih Topoecan (T) and Carboplatin (C) for Adults with Relapsed and Refractory Acute Leukemias

OSI-027, a Dual TORC1/TORC2 Inhibitor, Induces Bim- and Puma-Mediated Apoptosis In Lymphoid Malignancy

Dual Inhibition of mTORC1/mTORC2 Induces Apoptosis of Mantle Cell Lymphoma by Preventing Rictor Mediated AKT S473 Phosphorylation by Potentiating AKT2-PHLPP1 Association

A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas

Combinations of the Histone Deacetylase Inhibitor Entinostat (SNDX-275, MS-275) and Imatinib Have Divergent Effects in Imatinib-Sensitive Vs. Imatinib-Resistant p210- BCR/ABL Expressing Cell Lines.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only